Estimation of renal cell carcinoma treatment effects from disease progression modeling - Abstract

To improve future drug development efficiency in renal cell carcinoma (RCC), a disease-progression model was developed with longitudinal tumor size data from a phase III trial of sorafenib in RCC.

The best-fit model was externally evaluated on 145 placebo-treated patients in a phase III trial of pazopanib; the model incorporated baseline tumor size, a linear disease-progression component, and an exponential drug effect (DE) parameter. With the model-estimated effect of sorafenib on RCC growth, we calculated the power of randomized phase II trials between sorafenib and hypothetical comparators over a range of effects. A hypothetical comparator with 80% greater DE than sorafenib would have 82% power (one-sided α = 0.1) with 50 patients per arm. Model-based quantitation of treatment effect with computed tomography (CT) imaging offers a scaffold on which to develop new, more efficient, phase II trial end points and analytic strategies for RCC.

Written by:
Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR.   Are you the author?
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.

Reference: Clin Pharmacol Ther. 2013 Apr;93(4):345-51.
doi: 10.1038/clpt.2012.263


PubMed Abstract
PMID: 23443753

UroToday.com Renal Cancer Section